TCTMD

BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure

SAN RAMON, Calif., and VILNIUS, Lithuania, BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the first-in-man use of its next ...
TCTMD

BioVentrix Announces Milestone Achievement of its First Interventional Heart Failure Procedure for LV Volume Reduction in a Pre-Clinical Mode

SAN RAMON, Calif. and BORDEAUX, France, BioVentrix Inc., a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), announced today that it has achieved the first ever ...
Business Insider

BioVentrix announces the 1st Revivent TC™ TransCatheter commercial procedure to treat Ischemic Cardiomyopathy in China

SAN RAMON, Calif., and XIAMEN, China, March 13, 2017 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced ...
Business Insider

FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC® System for the Treatment of Ischemic Heart Failure

Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix ®, Inc., a privately held medical device company focused on ...
Business Wire

ADDING MULTIMEDIA BioVentrix receives CE mark for its Revivent® Myocardial Anchoring System

New hope for heart failure patients too sick or fragile to undergo standard open-heart surgery to treat damaged left ventricle “Our first commercial product, the Revivent™ Myocardial Anchoring System, ...
Pharmabiz

BioVentrix's image fusion-guided Revivent TC system successfully implanted in patient suffering from NYHA class III ischemic heart failure

BioVentrix a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), has announced the first image fusion-guided procedure with its Revivent TC system. The procedure, ...
Business Wire

BioVentrix Announces Gregg Stone, MD, as Co-Principal Investigator for ALIVE Pivotal Trial of Transcatheter Device for Heart Failure

SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New ...
Tennessean

BioVentrix, Inc. Announces German Reimbursement Designation

91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy Our team has successfully secured full reimbursement in Germany. Obtaining NUB Status 1a again for 2026 is an important ...